INTRODUCTION {#S1}
============

Neuroblastoma is the most common extracranial solid tumor of childhood. Most children have metastatic disease at diagnosis, and require aggressive therapy including chemotherapy, surgery and radiation, with autologous hematopoietic cell transplantation (auto-HCT) as consolidation ^[@R1],\ [@R2]^. In a randomized clinical trial conducted by the Children's Cancer Group, auto-HCT resulted in better event-free survival than standard chemotherapy, which was confirmed on long-term follow-up of this cohort ^[@R3],\ [@R4]^. Neuroblastoma is one of the most common indications for auto-HCT in pediatrics; however, disease recurrence remains the main cause of treatment failure. Even when post-transplant anti-GD2 antibody therapy is incorporated, the 3-year disease-free survival rate from transplant is 65% at best^[@R5]^. Allo-HCT has been utilized as treatment for neuroblastoma. However, limited comparisons of autologous vs. allogeneic HCT have not shown an advantage for allo-HCT ^[@R6],\ [@R7]^, and a retrospective review by the EBMT suggested that successful outcomes after allo-HCT have been limited by unacceptably high rates of regimen- related mortality and disease recurrence ^[@R8]^. More recently, with improvements in supportive care, improved HLA typing and the advent of reduced intensity conditioning regimens, physicians have been re-exploring allo-HCT ^[@R9]-[@R12]^. We therefore performed a retrospective study to describe the use of allo-HCT for neuroblastoma and to evaluate the outcomes of recipients of allo-HCT for neuroblastoma among patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).

METHODS {#S2}
=======

Data collection {#S3}
---------------

CIBMTR is a research affiliation of the International Bone Marrow Transplant Registry (IBMTR), the Autologous Blood and Marrow Transplant Registry (ABMTR) and the National Marrow Donor Program (NMDP) that comprises a voluntary working group of more than 500 transplantation centers worldwide that contribute data on consecutive HCT to a Statistical Center at the Medical College of Wisconsin and the NMDP. Participating centers are required to report all consecutive transplants; compliance is monitored by on-site audits. Computerized checks for errors, physicians' review of submitted data, and on-site audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are done with a waiver of informed consent and in compliance with HIPAA regulations as determined by the Institutional Review Board (IRB) and the Privacy Officer of the Medical College of Wisconsin.

Study population {#S4}
----------------

There were 3528 transplants (autologous or allogeneic) registered to the CIBMTR between 1990 and 2007 for neuroblastoma. This study was restricted to subjects with neuroblastoma undergoing a first allo-HCT from 1990 to 2007. All surviving recipients who received transplants from unrelated donors (URD) included in this analysis were retrospectively contacted and provided informed consent for participation in the NMDP research program. Informed consent for retrospective data analysis was waived by the NMDP IRB for all deceased patients. Surviving patients who did not provide signed informed consent to allow analysis of their clinical data were excluded. To adjust for potential bias introduced by exclusion of non-consenting surviving patients, a corrective action plan (CAP)--modeling process randomly excluded approximately the same percentage of deceased patients using a biased coin randomization with exclusion probabilities based on characteristics associated with not providing consent for use of data in survivors. The classification of degree of HLA-match was based on the model proposed by Weisdorf et al ^[@R13]^. In this schema "well-matched" category included those with no defined mismatches and no untested HLA locus; partially-matched included those with only one untested or mismatched locus; and mismatched included those with two or more known or mismatched or untested HLA-loci.

The study population included 143 subjects with neuroblastoma (4% of all transplants for neuroblastoma performed during this time period). We categorized patients into 2 groups, based on whether they had a history of a prior auto-HCT, with 97 patients not having a prior autograft and 46 patients having a prior autograft, registered with CIBMTR. A subset of these patients had more detailed report forms available (n=66) and are described in [Table 2](#T2){ref-type="table"}. Definitions and categorization of donor recipient HLA-matching and conditioning regimens were assigned according to published CIBMTR criteria^[@R14],\ [@R15]^. Patient-, disease-, and transplant-related characteristics are listed in [Table 1](#T1){ref-type="table"} for the entire group and in [Table 2](#T2){ref-type="table"} for the subgroup that had report forms available.

Endpoints and Definitions {#S5}
-------------------------

The primary objective was to describe the overall (OS) and disease-free survival (DFS) after allo-HCT for neuroblastoma and to describe the usage of this modality. In addition, we analyzed time to engraftment, incidence of acute and chronic GVHD, relapse or disease progression and transplant related mortality (TRM). Neutrophil engraftment was defined as the first of three consecutive days with an absolute neutrophil count of ≥ 0.5 × 10^9^/L; platelet engraftment was defined as platelet count ≥ 20 × 10^9^/L for seven consecutive days without transfusion support. TRM was defined as death from any cause in the first 28 days or death without evidence of disease progression/relapse. Relapse was defined as recurrence of neuroblastoma after a complete response (CR) or progression of disease at existing sites, or new sites of disease. For calculating DFS, patients were considered treatment failures at relapse or progression, or death. The OS interval variable was defined as the time from date of transplant to date of death or last contact. Acute GVHD was defined and graded based on the pattern and severity of organ involvement using established criteria^[@R16]^. Chronic GVHD was defined as the development of any chronic GVHD based on clinical criteria^[@R17]^.

Statistical analysis {#S6}
--------------------

Patient-, disease-, and transplant-related variables ([Table 1](#T1){ref-type="table"}) were described with median and range for continuous variables, and percent of total for categorical variables. Occurrence of acute and chronic GVHD, TRM, and disease recurrence/progression were calculated using cumulative incidence estimates, taking into account the competing risks. Probabilities of DFS and OS were estimated from the time of HCT using the Kaplan-Meier estimator. When possible, univariate analysis was performed to compare outcomes among the two groups of patients: patients without a prior auto-HCT (Group 1) and those with a prior auto-HCT (Group 2). All p-values were two-sided. All analyses were performed using SAS 9.1 (SAS Institute, Cary, NC).

RESULTS {#S7}
=======

Subjects, disease, transplant characteristics {#S8}
---------------------------------------------

Median age was 5 years (range, \<1-55 years) in Group 1 and 7 years (range, 2-32 years) in group 2 ([table 1](#T1){ref-type="table"}). 40% of subjects in Group 1 and 61% of subjects in Group 2 had a Karnofsky/Lansky performance score \> 90. The median time to allo-HCT from auto-HCT was 20 months (range, 1-68 months). A subgroup of 66 patients (35 in Group 1, 31 in Group 2) had more extensive data collected and was available for additional analysis ([Table 2](#T2){ref-type="table"}).

Graft-versus-host disease {#S9}
-------------------------

The incidence of grade II-IV acute GVHD was 28% (95% CI 20-37%) by 100 days post HCT. The incidence of chronic GVHD was 14% (95% CI 8-21%) at 1 year ([Table 3a](#T3){ref-type="table"}). In an analysis of relapse evaluating the impact of GVHD, no effect of acute GVHD (p=0.6738) on relapse was observed. Effect of chronic GVHD could not be estimated because of the low incidence of chronic GVHD (14%). There was no difference in the cumulative incidence of acute or chronic GVHD between the two patient cohorts studied ([Table 3b](#T4){ref-type="table"}).

Relapse {#S10}
-------

Cumulative incidences of neuroblastoma progression or relapse at 1 and 5 years post-HCT were 38% (95% CI 29-47%) and 55% (95% CI 45-64%), respectively, for all subjects ([Table 3a](#T3){ref-type="table"}). GVHD did not correlate with disease progression or relapse. Disease recurrence at 1 year post allo-HCT was observed more often in patients in Group 2 compared to Group 1 ([Table 3b](#T4){ref-type="table"}) (57% versus 27% at 1year, p=0.0012). This observation persisted at 3 and 5 years post-allo-HCT.

Treatment-related mortality {#S11}
---------------------------

TRM at 100 days post-HCT was 18% (95% CI 12-26%) for the entire study population. TRM was stable over the first 5 years after transplant: from 25% (95% CI 17-33%) at 1 year to 25% (95% CI 18-34%) at 3 years, to 25% (95% CI; 18-34%) at 5 years post-HCT. There was no difference in the cumulative incidence of TRM between the two patient cohorts studied ([Table 3b](#T4){ref-type="table"}).

Disease-free survival (DFS) {#S12}
---------------------------

For the entire cohort, DFS was 37% (95% CI 28-46%) at 1 year post-HCT and 20% (95% CI 13-27%) at 5 years post-HCT ([Table 3a](#T3){ref-type="table"}). Neither acute nor chronic GVHD correlated with DFS. DFS was higher for patients in Group 1 compared to Group 2 ([Table 3b](#T4){ref-type="table"}) (48% versus 19% at 1 year, p=0.0006).

Overall Survival (OS) {#S13}
---------------------

Survival at 1 year post HCT was 56% (95% CI 47-64%) and 22% (95% CI 15-30%) at 5 years post-HCT for all patients ([Table 3a](#T3){ref-type="table"}). Survival was higher for patients in Group 1 compared to Group 2 ([Table 3b](#T4){ref-type="table"}) (36% versus 16% at 3 years, p=0.0086).

Cause of death {#S14}
--------------

The most common cause of death among transplant recipients was disease recurrence (n=72, 68%). Other common causes included organ failure (n=8, 8%), infection (n=9, 8%), and GVHD (n=4, 4%) ([Table 5](#T8){ref-type="table"}). Of patients in Group 2, 87% died. Of patients in Group 1, 68% died.

Outcome by donor type {#S15}
---------------------

Time to neutrophil engraftment, platelet engraftment, acute GVHD, chronic GVHD, and TRM were unaffected by donor type ([Table 3c](#T5){ref-type="table"}). Relapse was consistently higher for recipients of URD grafts compared to other hematopoietic graft sources. Similarly, early DFS (at 1 year) and OS (at 1 and 3 years) was lower for URD grafts. A separate analysis of the 33 patients undergoing cord blood transplantation was performed ([Table 6](#T9){ref-type="table"}); 16 did not undergo prior auto-HCT. In this subgroup, the day 100 TRM was 19%, plateauing at 23% from 1 year to 5 year post-HCT. One-year DFS was 20%.

Outcome by disease status at allogeneic HCT {#S16}
-------------------------------------------

Time to neutrophil engraftment, platelet engraftment, acute GVHD, chronic GVHD, and TRM were unaffected by disease status at allo-HCT ([Table 3d](#T6){ref-type="table"}). The incidence of relapse at one year was significantly lower for patients in complete response (CR) or very good partial response (VGPR) at allo-HCT, but this effect was not statistically significant at 3 and 5 years after allo-HCT. However, DFS and OS were consistently significantly higher for patients transplanted in CR or VGPR compared to patients with more advanced disease. This observation held throughout the first 5 years following allo-HCT.

Outcome for patients without prior auto-HCT in CR, VGPR, or PR {#S17}
--------------------------------------------------------------

For the patients proceeding directly to allo-HCT (with no prior history of auto-HCT) in CR, VGPR, or PR, the treatment-related mortality was 15%, with no occurrences after the first 100 days post-HCT ([Table 4](#T7){ref-type="table"}). DFS declined from 59% at 1-year post --HCT to 37% at 5-years post-HCT. Disease recurrence rates at 1-year post-HCT were 26%, rising to 48% at 5-years post-HCT.

Outcome by conditioning regimen {#S18}
-------------------------------

The majority of patients received a myeloablative conditioning regimen (67%). Of the 96 patients receiving an ablative regimen, only 19 had undergone prior auto-HCT. Of the 35 receiving a reduced intensity or non-myeloablative regimen (RIC), 20 had undergone a prior auto-HCT. TRM was significantly lower at 100 days post-HCT for those receiving a reduced intensity regimen (9% versus 23%, p-0.0437) but was not statistically significant thereafter. Recipients of RIC regimens had higher relapse rates at all time points post-HCT. DFS at one-year and OS at 3 years post-HCT ([Table 7](#T10){ref-type="table"}), were lower for recipients of RIC regimens.

DISCUSSION {#S19}
==========

This study demonstrates that allo-HCT for neuroblastoma is uncommon, accounting for 4% of all transplants for neuroblastoma in this publication and 3% (124 of 4098) reported by EBMT (8). In this cohort of patients with high-risk neuroblastoma, 20% (95% CI 13-27%) of subjects were alive without disease recurrence at five years after allo-HCT. Reflecting improvements in HCT practice, in this cohort graft failure and TRM were not significant causes of treatment failure; however, disease recurrence remained the most common barrier to transplant success. It is important to recognize that this study population included only first allogeneic transplants, and excluded those who had undergone prior allo-HCT. However, as expected for patients with high-risk neuroblastoma, a significant proportion of patients had undergone prior autologous transplantation, which is the standard treatment for these patients. However, it was surprising that 68% of the patients had not undergone prior autologous transplantation, receiving allogeneic transplant as their initial transplant consolidative therapy. Therefore, a portion of this patient population is unique in that the treating physicians proceeded directly to allo-HCT rather than auto-HCT.

Most series of auto-HCT report DFS rates approximating 45% from diagnosis with relapse being the most common cause of patient mortality^[@R3],\ [@R4]^, although two phase 2 trials utilizing multiple cycles of HCT have reported DFS rates of \~55% ^[@R18]-[@R20]^. Persistent disease may cause relapse, although it has also been hypothesized that disease contamination in infused stem cells may also contribute to recurrence ^[@R3],\ [@R4],\ [@R21]^. However, tumor cell contamination in PBSC is low, even when the cells are collected from a patient with residual tumor in the marrow^[@R22]^, and a recent trial from the Children's Oncology Group failed to detect an impact of tumor cell purging of PBSC used for auto-HCT^[@R23]^. Using allogeneic marrow certainly avoids the possibility of infusing contaminating tumor in the PBSC product, but at the expense of the complications of allogenicity such as graft failure, GVHD and delayed immune reconstitution. In this series the authors cannot comment on why some patients proceeded directly to allo-HCT and did not undergo auto-HCT. This decision was made by the treating physician and the registry does not collect this information. It is conceivable that patients were unable to have adequate numbers of autologous hematopoietic progenitor cells collected, were unable to have tumor-free grafts obtained, or had progressive disease making auto-HCT impractical. Certainly patients who had a matched related donor seemed to be more common in our series than other allogeneic donor types.

Recently, with the addition of the post-transplant immunotherapy with the chimeric anti-GD2 antibody, the Children's Oncology Group has reported DFS rates approaching 65% from the point of auto-HCT for neuroblastoma ^[@R5]^. There are no large series of outcomes for allo-HCT in neuroblastoma, with the present report being the largest series collected to date. Recently, at the 2012 EBMT meeting, a group from Japan reported on retrospective outcomes after allo UCBT for neuroblastoma^[@R24]^. In a cohort of 75 patients, differences were again seen between those in a first CR/VGPR vs. other patients (51.5% 3 year EFS vs. 38.5%, respectively). Although a direct comparison is not possible, the overall 3 year EFS of the UCBT group in our cohort was 17%. Case reports and small series have suggested that a graft-versus-malignancy effect may exist, but investigators are unable to quantify the survival advantage, if any, that is seen with this modality^[@R9]-[@R11],\ [@R25]^. There is indirect evidence that neuroblastoma may respond to a graft-versus-tumor effect after allo-HCT or other immunomodulatory therapies. This observation is supported by the use of such therapies to treat this disorder using dendritic cells, natural killer cells, and anti-GD2 antibodies^[@R26],\ [@R27]^. The DFS rates reported in this study are inferior for the entire group when compared to the baseline of 45-55% reported for auto-HCT. However, a direct comparison is not possible given the potential differences in disease responsiveness and relapse risk between Group 1, Group 2, and large reported cohorts of neuroblastoma patients who underwent auto-HCT after induction chemotherapy. When examining the patients in Group 1, the DFS rates compare favorably given the degree of HLA mismatch between donors and recipients, the percentage of recipients with poor performance scores, and the extensive prior therapy of this patient population. The use of novel agents such as immunomodulatory agents and radioactive treatments may further increase survival ^[@R28]^.

These outcomes, however, remain poor. Although 37% of subjects were alive in remission at one year after HCT, only 20% were alive and free of disease progression at five years post HCT. For recipients who had not received a prior auto-HCT, 48% and 27% were alive and in remission at one and five years post-allogeneic HCT, respectively. It is quite likely that this group was at higher risk for relapse than a group of patients undergoing auto-HCT for consolidation after induction therapy. Only 23% of this group had chemosensitive disease (judged by their treating physician) although many of them were in CR, VGPR, or PR. Thus, it is difficult to discern a positive impact of allo-HCT in this group of patients without clearer data regarding disease risk. Patients who had undergone an auto-HCT at any point prior to allo-HCT had extremely poor outcomes, with 19% and 6% alive and in remission at 1 and 5 years post-allo-HCT. In addition to the fact that the patients in Group 2 likely had higher-risk disease than those in Group 1, potential reasons for the differences in Group 1 and Group 2 include: i) that there was a fraction of patients undergoing allo-HCT without a prior autograft who would have been cured using a conventional auto-HCT, ii) less treatment prior to the allograft, or ii) the possibility that the use of allo-HCT earlier prevented the development of tumor resistance.

It is noteworthy that even patients with chemotherapy-resistant disease were curable in our series, suggesting that in some cases an immunologic graft-versus-tumor effect may be operational, although in this series there was no relationship between outcome and acute or chronic GVHD, similar to other reports ^[@R9]-[@R11],\ [@R26]^. It is possible that another immunologic mechanism distinct from GVHD may be mediating the antitumor effects ^[@R4]^. Our study supports the observation that chemotherapy-resistant disease is a marker for poor outcome, although it may not be an absolute contraindication to allo-HCT. It is unclear which portions of the donor immune system, if any, mediate this effect. It is postulated that T-cell alloreactivity of NK cell mediated cell destruction may be operational ^[@R29],\ [@R30]^, but has not been clearly demonstrated.

The study is limited by its retrospective nature and the lack of data regarding the underlying reasons behind the clinical decisions to utilize allo-HCT. A significant number of the recipients in this trial had low performance scores and chemorefractory disease ([Table 1](#T1){ref-type="table"}). These characteristics suggest that the treating clinicians were considering an allo-HCT to reduce relapse rates in this high-risk group. This analysis does not attempt to compare outcomes of subjects with neuroblastoma based on donor-recipient relationship or HLA mismatch. Our results suggest that allo-HCT can result in long-term DFS in some patients with neuroblastoma. However, it is unclear which patients may benefit from this modality. Future investigation of allogeneic approaches in this disease should focus on dissecting immunological parameters that define an increased likelihood of a graft-vs.-neuroblastoma effect, hopefully leading to decreases in post-transplant disease recurrence and improved survival in patients with resistant disease^[@R30]^.
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###### 

Characteristics of patients receiving allogeneic transplantation for neuroblastoma between 1990-2007 and registered to the CIBMTR

  -----------------------------------------------------------------------------------------------
  Characteristics of patients                                Did not receive\   Received prior\
                                                             prior auto,\       auto,\
                                                             N (%)              N (%)
  ---------------------------------------------------------- ------------------ -----------------
  Number of patients                                         97                 46

  Number of centers                                          48                 24

  Age at transplant, median (range), years                   5 (\<1- 55)        7 (2-32)

   0 -- 5                                                    51 (53)            9 (20)

   6 -10                                                     27 (28)            31 (67)

   11 -- 20                                                  13 (13)            5 (11)

   \> 20                                                     6 ( 6)             1 ( 2)

  Male sex                                                   58 (60)            23 (50)

  Karnofsky score prior to TX                                                   

   \< 90%                                                    13 (13)            11 (24)

   ≥ 90%                                                     39 (40)            28 (61)

   Unknown                                                   45 (46)            7 (15)

  Time from diagnosis to allogeneic transplant                                  

   Median (range), months                                    9 (\<1-97)         27 (8 - 76)

   ≤ 6                                                       12 (12)            0

   7 12                                                      50 (52)            3 ( 7)

   13 -- 24                                                  19 (20)            10 (22)

   25 -- 36                                                  6 ( 6)             18 (39)

   \> 36                                                     9 ( 9)             15 (33)

   Missing                                                   1 ( 1)             0

  Had prior autologous transplant                                               46 (100)

  Time from autologous transplant to allogeneic transplant                      

   Median (range), months                                    NA                 20 (1- 68)

   0 - 12                                                                       10 (22)

   13 -- 24                                                                     19 (41)

   24 -- 36                                                                     17 (37)

  Disease status prior to transplant                                            

   CR                                                        30 (31)            8 (17)

   Very good partial response                                8 ( 8)             4 ( 9)

   Partial response                                          17 (18)            8 (17)

   Minimal response                                          1 ( 1)             1 ( 2)

   No response                                               17 (18)            2 ( 4)

   Progressive disease                                       6 ( 6)             11 (24)

   Unknown                                                   18 (19)            12 (26)

  Conditioning regimen                                                          

   TBI + other                                               59 (61)            15 (33)

   Bu + CY ± Other                                           4 ( 4)             1 (2)

   CY + other                                                6 ( 6)             7 (15)

   Bu + Fludara ± Other                                      3 ( 3)             6 (13)

   Bu + Other                                                1 ( 1)             3 ( 7)

   Melphalan + Fludara ± other                               3 ( 3)             9 (20)

   Melphalan ± Other                                         11 (11)            0

   Other^a^                                                  2 ( 2)             0

   Unknown                                                   8 ( 8)             5 (11)

  Donor type                                                                    

   HLA-identical sibling                                     56 (58)            18 (39)

   Other related donor                                       25 (26)            4 (9)

   Unrelated                                                 16 (16)            24 (52)

  Graft source                                                                  

   BM                                                        69 (71)            16 (35)

   PBSC                                                      10 (10)            13 (28)

   Cord Blood                                                16 (16)            17 (37)

   Unknown                                                   2 (2)              0

  Year of transplant                                                            

   1990 -- 1994                                              38 (39)            1 ( 2)

   1995 -- 1999                                              26 (27)            10 (22)

   2000 -- 2004                                              24 (25)            18 (39)

   2005 -- 2007                                              9 ( 9)             17 (37)

  GVHD prophylaxis                                                              

   T-cell depletion                                          5 ( 5)             1 ( 2)

   MTX + CSA ± other                                         21 (22)            9 (20)

   MTX ± other                                               19 (20)            3 (7)

   CSA ± Other                                               30 (31)            23 (50)

   Other                                                     1 ( 1)             3 ( 7)

   Unknown^b^                                                21 (22)            7 (15)

  Median (range) follow-up ^c^, months                       84 (\<1- 191)      45 (\<1- 58)
  -----------------------------------------------------------------------------------------------

Abbreviations: TBI = total body irradiation; CY = cyclophosphamide; CsA = cyclosporine; MTX = methotrexate; CMV = cytomegalovirus; GVHD = graft-versus-host disease; FK506 = tacrolimus.

###### 

Characteristics of patients receiving allogeneic transplantation for neuroblastoma between 1990-2007 and reported to the CIBMTR

  --------------------------------------------------------------------------------------------------------------
  Characteristics of patients                             Did not receive prior auto,\   Received prior auto,\
                                                          N (%)                          N (%)
  ------------------------------------------------------- ------------------------------ -----------------------
  Number of patients^a^                                   35                             31

  Number of centers                                       24                             19

  Age at transplant, median (range), years                5 (2-39)                       7 (1-32)

   0 -- 5                                                 18 (51)                        7 (23)

   6 -10                                                  9 (26)                         20 (65)

   11 -- 20                                               5 (14)                         3 (10)

   \> 20                                                  3 ( 9)                         1 ( 3)

  Male sex                                                17 (49)                        12 (39)

  Karnofsky score prior to TX                                                            

   \< 90%                                                 13 (37)                        9 (29)

   ≥ 90%                                                  21 (60)                        20 (65)

   Unknown                                                1 (3)                          2 (6)

  Time from diagnosis to allogeneic transplant                                           

   Median (range), months                                 11 (5-97)                      27 (9-76)

   0 -- 6                                                 3 ( 9)                         0

   7 12                                                   17 (49)                        3 (10)

   13 -- 24                                               7 (20)                         5 (16)

   25 -- 36                                               2 (6)                          13 (42)

   \> 36                                                  6 (17)                         10 (32)

  Had prior autologous transplant\                                                       
  Time from autologous transplant to allogeneic\                                         
  transplant                                                                             

   Median (range), months                                                                19 (1-68)

   0 - 12                                                 NA                             8 (26)

   13 - 24                                                                               12 (39)

   24 -- 36                                                                              11 (35)

  Disease status prior to transplant                                                     

   CR                                                     9 (26)                         5 (16)

   Very good partial response                             3 ( 9)                         4 (13)

   Partial response                                       9 (26)                         7 (23)

   Minimal response                                       1 (3)                          1 (3)

   No response                                            4 (11)                         1 (3)

   Progressive disease                                    3 ( 9)                         5 (16)

   Unknown                                                6 (17)                         8 (26)

  Conditioning regimen                                                                   

   TBI + other                                            18 (51)                        10 (32)

   Bu + CY ± other                                        3 ( 9)                         1 ( 3)

   CY + other                                             4 (11)                         6 (19)

   Bu + Fludara ± other                                   2 ( 6)                         6 (19)

   Bu + other                                             1 ( 3)                         2 ( 6)

   Fludara + Melphalan                                    1 ( 3)                         6 (19)

   Melphlan + other                                       5 (14)                         0

   Etopside + Carboplatin                                 1 ( 3)                         0

  Donor recipient HLA match                                                              

   HLA-identical sibling                                  18 (51)                        10 (32)

   Other related donor                                    3 ( 9)                         2 ( 6)

   Matched unrelated donor                                0                              5 (16)

   Mismatched unrelated donor                             14 (40)                        13 (42)

   Matching unknown, unrelated donor                      0                              1 ( 3)

  Graft source                                                                           

   BM                                                     16 (46)                        11 (35)

   PBSC                                                   4 (11)                         8 (26)

   Cord Blood                                             15 (43)                        12 (39)

  Year of transplant                                                                     

   1990 -- 1994                                           14 (40)                        1 ( 3)

   1995 -- 1999                                           5 (14)                         8 (26)

   2000 -- 2004                                           12 (34)                        9 (29)

   2005 -- 2007                                           4 (11)                         13 (42)

  GVHD prophylaxis                                                                       

   T-cell depletion                                       3 ( 9)                         1 ( 3)

   MTX + CSA ± other                                      8 (23)                         7 (23)

   MTX ± other                                            4 (11)                         2 ( 6)

   CSA ± Other                                            17 (49)                        17 (55)

   Fk506 ± Other                                          0                              2 (6)

   Unknown^b^                                             3 (9)                          2 (6)

  Previous bone marrow involvement                                                       

   No                                                     4 (11)                         6 (19)

   Yes                                                    10 (29)                        14 (45)

   Unknown                                                21 (60)                        11 (35)

  Previous CNS involvement                                                               

   No                                                     12 (34)                        19 (61)

   Yes                                                    2 (6)                          1 (3)

   Unknown                                                21 (60)                        11 (35)

  Metastases present at diagnosis                                                        

   No                                                     1 ( 3)                         2 ( 6)

   Yes                                                    14 (40)                        16 (52)

   Missing                                                20 (57)                        13 (42)

  disease INSS stage at diagnosis                                                        

   Stage 1                                                1 ( 3)                         0

   Stage 3                                                4 (11)                         3 (10)

   Stage 4                                                10 (29)                        14 (45)

   Missing                                                20 (57)                        14 (45)

  Number of sites of disease at allogeneic transplant                                    

   1                                                      1 ( 3)                         3 (10)

   2                                                      3 ( 9)                         3 (10)

   3                                                      2 ( 6)                         2 ( 6)

   4                                                      1 ( 3)                         2 ( 6)

   Missing                                                16 (46)                        12 (39)

   NA (disease status was CR, VGPR)                       12 (34)                        9 (29)

  Chemo sensitive to last line of therapy                                                

   No                                                     2 ( 6)                         1 ( 3)

   Yes                                                    8 (23)                         12 (39)

   did not receive chemotherapy as last line of therapy   2 ( 6)                         0

   Missing                                                23 (66)                        18 (58)

  Radiotherapy given as part of initial treatment                                        

   No                                                     12 (34)                        12 (39)

   Yes (primary tumor bed after resection as sit of\      1 ( 3)                         2 ( 6)
  radiotherapy)                                                                          

   Unknown                                                22 (63)                        17 (55)

  Donor-recipient sex match                                                              

   M -- M                                                 9 (26)                         4 (13)

   M -- F                                                 9 (26)                         7 (23)

   F -- M                                                 8 (23)                         6 (19)

   F -- F                                                 8 (23)                         10 (32)

   Unknown                                                1 ( 3)                         4 (13)

  Donor-recipient CMV status                                                             

   −/−                                                    17 (49)                        11 (35)

   +/−                                                    3 ( 9)                         3 (10)

   −/+                                                    10 (29)                        9 (29)

   +/+                                                    3 ( 9)                         4 (13)

   Unknown                                                2 ( 6)                         4 (13)

  Median (range) follow-up ^c^, months                    72 (3-150)                     45 (3-58)
  --------------------------------------------------------------------------------------------------------------

Abbreviations: TBI = total body irradiation; CY = cyclophosphamide; CsA = cyclosporine; MTX = methotrexate; CMV = cytomegalovirus; GVHD = graft-versus-host disease; FK506 = tacrolimus.

###### 

Univariate probabilities of outcomes of all patients

  Outcome event                  All patients with available outcome data   
  ------------------------------ ------------------------------------------ ------------
  ANC \> 0.5 × 10^9^/L           111                                        
    @ 28 days                                                               83 (74-89)
    \@100 days                                                              92 (85-96)
  Platelets \> 20 × 10^9^ /L     95                                         
   @ 60 days                                                                57 (46-67)
   \@100 days                                                               60 (49-70)
  Acute GVHD, Grades 2-4         103                                        
    \@100 days                                                              28 (20-37)
    @ 180 days                                                              29 (21-38)
  Chronic GVHD                   112                                        
    @ 1 year                                                                14 (8-21)
    @ 3 years                                                               15 (9-22)
    \@5 years                                                               15 (9-22)
  Transplant-related mortality   115                                        
    @ 100days                                                               18 (12-26)
    @ 1 year                                                                25 (17-33)
    @ 3 years                                                               25 (18-34)
    @ 5 years                                                               25 (18-34)
  Relapse                        115                                        
    @ 1 year                                                                38 (29-47)
    @ 3 years                                                               52 (42-61)
    @ 5 years                                                               55 (45-64)
  Disease-free survival          115                                        
    @ 1 year                                                                37 (28-46)
    @ 3 years                                                               23 (15-31)
    @ 5 years                                                               20 (13-27)
  Overall survival               143                                        
    @ 1 year                                                                56 (47-64)
    @ 3 years                                                               29 (22-37)
    @ 5 years                                                               22 (15-30)

###### 

Univariate probabilities of outcomes by whether received prior autologous transplant

                                 Did not receive prior auto   Received prior auto   P-value                 
  ------------------------------ ---------------------------- --------------------- --------- ------------- --------
  ANC \> 0.5 × 10^9^/L           69                                                 42                      
    @ 28 days                                                 78 (66-86)                      90 (76-96)    0.0806
    \@100 days                                                88 (78-94)                      98 (84-100)   0.0433
  Platelets \> 20 × 10^9^ /L     54                                                 41                      
   @ 60 days                                                  65 (50-76)                      47 (28-64)    0.1309
   \@100 days                                                 69 (54-79)                      50 (30-67)    0.1115
  Acute GVHD, Grades 2-4         65                                                 38                      
    \@100 days                                                23 (14-34)                      37 (22-52)    0.1466
    @ 180 days                                                25 (15-36)                      37 (22-52)    0.202
  Chronic GVHD                   68                                                 44                      
    @ 1 year                                                  10 (5-19)                       19 (9-32)     0.2359
    @ 3 years                                                 12 (6-21)                       19 (9-32)     0.3395
    \@5 years                                                 12 (6-21)                       19 (9-32)     0.3395
  Transplant-related mortality   73                                                 42                      
    @ 100days                                                 19 (11-29)                      17 (7-29)     0.7332
    @ 1 year                                                  25 (16-35)                      24 (12-37)    0.8916
    @ 3 years                                                 26 (17-37)                      24 (12-37)    0.7572
    @ 5 years                                                 26 (17-37)                      24 (12-37)    0.7572
  Relapse                        73                                                 42                      
    @ 1 year                                                  27 (17-38)                      57 (41-70)    0.0012
    @ 3 years                                                 43 (31-55)                      67 (50-79)    0.0131
    @ 5 years                                                 46 (34-58)                      70 (53-82)    0.0123
  Disease-free survival          73                                                 42                      
    @ 1 year                                                  48 (36-59)                      19 (9-32)     0.0006
    @ 3 years                                                 30 (20-41)                      10 (3-21)     0.0037
    @ 5 years                                                 27 (17-38)                      6 (1-17)      0.0018
  Overall survival               97                                                 46                      
    @ 1 year                                                  59 (48-68)                      50 (35-64)    0.3439
    @ 3 years                                                 36 (26-46)                      16 (7-28)     0.0086
    @ 5 years                                                 29 (20-39)                      7 (1-18)      0.0005

###### 

Univariate probabilities of outcomes by donor type

                                 HLA-identical sibling   Other related   Unrelated   P-value                        
  ------------------------------ ----------------------- --------------- ----------- ------------ ---- ------------ ---------
  ANC \> 0.5 × 10^9^/L           50                                      23                       38                
    @ 28 days                                            86 (72-93)                  87 (64-96)        76 (59-87)   0.4703
    \@100 days                                           92 (80-97)                  87 (64-96)        95 (81-99)   0.6149
  Platelets \> 20 × 10^9^ /L     39                                      19                       37                
   @ 60 days                                             65 (48-78)                  63 (38-80)        45 (27-61)   0.199
   \@100 days                                            68 (50-81)                  63 (38-80)        51 (32-66)   0.3311
  Acute GVHD, Grades 2-4         51                                      19                       33                
    \@100 days                                           25 (15-38)                  21 (7-41)         36 (20-52)   0.4306
    @ 180 days                                           25 (15-38)                  21 (7-41)         40 (23-56)   0.2802
  Chronic GVHD                   53                                      21                       38                
    @ 1 year                                             12 (5-22)                   19 (6-38)         14 (5-27)    0.7333
    @ 3 years                                            12 (5-22)                   24 (9-43)         14 (5-27)    0.489
    \@5 years                                            12 (5-22)                   24 (9-43)         14 (5-27)    0.489
  Transplant-related mortality   55                                      21                       39                
    @ 100days                                            18 (9-29)                   19 (6-38)         18 (8-31)    0.9944
    @ 1 year                                             24 (14-36)                  34 (15-54)        21 (10-34)   0.5397
    @ 3 years                                            26 (15-38)                  34 (15-54)        21 (10-34)   0.5397
    @ 5 years                                            26 (15-38)                  34 (15-54)        21 (10-34)   0.5436
  Relapse                        55                                      21                       39                
    @ 1 year                                             30 (18-42)                  15 (4-33)         63 (46-76)   \<.0001
    @ 3 years                                            52 (38-64)                  25 (9-45)         66 (49-79)   0.0043
    @ 5 years                                            56 (41-68)                  31 (13-51)        66 (49-79)   0.0263
  Disease-free survival          55                                      21                       39                
    @ 1 year                                             47 (33-59)                  51 (28-70)        16 (7-29)    0.0007
    @ 3 years                                            22 (12-34)                  41 (20-61)        13 (5-26)    0.079
    @ 5 years                                            19 (10-30)                  35 (15-55)        13 (5-26)    0.2133
  Overall survival               74                                      29                       40                
    @ 1 year                                             63 (51-73)                  60 (39-75)        40 (25-55)   0.0529
    @ 3 years                                            30 (19-41)                  48 (28-65)        16 (7-29)    0.0175
    @ 5 years                                            22 (13-33)                  33 (16-52)        16 (7-29)    0.3101

###### 

Univariate probabilities of outcomes by disease status prior to transplant

                                 CR, VGPR                PR   MR, NR, Progressive   P-value                
  ------------------------------ ---------- ------------ ---- --------------------- --------- ------------ ---------
  ANC \> 0.5 × 10^9^/L           41                      20                         28                     
    @ 28 days                               85 (69-93)        80 (55-92)                      89 (68-97)   0.6971
    \@100 days                              93 (78-98)        100                             89 (68-97)   
  Platelets \> 20 × 10^9^ /L     34                      19                         25                     
   @ 60 days                                69 (50-82)        57 (30-76)                      48 (27-66)   0.2639
   \@100 days                               72 (53-85)        62 (35-81)                      52 (31-70)   0.2919
  Acute GVHD, Grades 2-4         36                      19                         25                     
    \@100 days                              19 (9-34)         32 (13-52)                      36 (18-55)   0.3178
    @ 180 days                              19 (9-34)         32 (13-52)                      40 (21-58)   0.2031
  Chronic GVHD                   41                      20                         28                     
    @ 1 year                                5 (1-15)          10 (2-28)                       25 (11-42)   0.0755
    @ 3 years                               7 (2-18)          10 (2-28)                       25 (11-42)   0.1634
    \@5 years                               7 (2-18)          10 (2-28)                       25 (11-42)   0.1634
  Transplant-related mortality   41                      19                         33                     
    @ 100days                               15 (6-27)         21 (7-41)                       24 (11-40)   0.5641
    @ 1 year                                15 (6-27)         21 (7-41)                       36 (21-52)   0.0973
    @ 3 years                               15 (6-27)         21 (7-41)                       36 (21-52)   0.0973
    @ 5 years                               15 (6-27)         21 (7-41)                       36 (21-52)   0.0973
  Relapse                        41                      19                         33                     
    @ 1 year                                18 (8-31)         67 (41-84)                      48 (31-64)   \<.0001
    @ 3 years                               44 (28-59)        67 (41-84)                      55 (36-70)   0.223
    @ 5 years                               47 (30-61)        67 (41-84)                      61 (42-75)   0.2627
  Disease-free survival          41                      19                         33                     
    @ 1 year                                67 (50-80)        12 (2-31)                       16 (6-29)    \<.0001
    @ 3 years                               41 (26-56)        12 (2-31)                       9 (2-22)     0.0019
    @ 5 years                               39 (24-54)        12 (2-31)                       3 (0-13)     0.0001
  Overall survival               50                      25                         38                     
    @ 1 year                                79 (65-88)        43 (22-62)                      39 (24-55)   \<.0001
    @ 3 years                               52 (37-65)        14 (4-32)                       11 (4-24)    \<.0001
    @ 5 years                               47 (32-61)        9 (2-26)                        6 (1-16)     \<.0001

Abbreviations: VGPR- Very good partial response; PR- Partial response; MR- Minimal response; NR- No response

Probabilities of ANC\>0.5 × 10^9^/L, Platelets \> 20 × 10^9^ /L, acute GVHD, chronic GVHD, treatment related mortality and relapse were calculated using the cumulative incidence estimate. Probabilities of overall survival and disease free survival were calculated using the Kaplan-Meier product limit estimate

###### 

Outcomes of patients by disease status prior to transplant for patients without prior auto transplants

  Outcome event                  In CR, VGPR, PR   In MR, NR, progressive   P-value                
  ------------------------------ ----------------- ------------------------ --------- ------------ ----------------------
  Transplant-related mortality   41                                         19                     
    @ 100days                                      15 (6-27)                          32 (13-52)   0.1582
    @ 1 year                                       15 (6-27)                          42 (20-62)   0.0292
    @ 3 years                                      15 (6-27)                          42 (20-62)   0.0292
    @ 5 years                                      15 (6-27)                          42 (20-62)   0.0292
  Relapse                        41                                         19                     
    @ 1 year                                       26 (13-40)                         37 (17-57)   0.4068
    @ 3 years                                      45 (29-60)                         47 (24-67)   0.8577
    @ 5 years                                      48 (31-62)                         53 (29-72)   0.7178
  Disease-free survival          41                                         19                     P~\_overall\<~0.0001
    @ 1 year                                       59 (42-73)                         21 (7-41)    0.0017
    @ 3 years                                      41 (25-55)                         11 (2-28)    0.0048
    @ 5 years                                      38 (23-53)                         5 (0-21)     0.0005
  Overall survival               55                                         24                     P~\_overall\<~0.0001
    @ 1 year                                       67 (52-78)                         44 (24-63)   0.0644
    @ 3 years                                      45 (31-59)                         13 (3-30)    0.0015
    @ 5 years                                      41 (27-54)                         9 (2-24)     0.0006

###### 

Cause of death

  --------------------------------------------------------------------------------------------
                       Did not receive prior auto,\   Received prior auto,\   All patients,\
                       N (%)                          N (%)                   N (%)
  -------------------- ------------------------------ ----------------------- ----------------
  Number of patients   97                             46                      143

  Number of death      66                             40                      106

   Primary disease     42 (64)                        30 (75)                 72 (68)

   Infection           7 (11)                         2 (5)                   9 (8)

   ARDS                3 (5)                          1 (3)                   4 (3)

   Organ failure       4 (6)                          4 (10)                  8 (8)

   Graft failure       1 (2)                          0 (.)                   1 (1)

   Hemorrhage          1 (2)                          1 (3)                   2 (2)

   GVHD                4 (5)                          0 (.)                   4 (4)

   Vascular            0 (.)                          1 (2)                   1 (1)

   Unknown             4 (5)                          1 (2)                   5 (5)
  --------------------------------------------------------------------------------------------

###### 

Outcomes of patients who had cord blood transplants

  Outcome event                       
  ------------------------------ ---- ------------
  Transplant-related mortality        
    @ 100days                    31   19 (8-35)
    @ 1 year                          23 (10-39)
    @ 3 years                         23 (10-39)
    @ 5 years                         23 (10-39)
  Relapse                        31   
    @ 1 year                          57 (37-72)
    @ 3 years                         60 (41-75)
    @ 5 years                         60 (41-75)
  Disease-free survival          31   
    @ 1 year                          20 (8-36)
    @ 3 years                         17 (6-32)
    @ 5 years                         17 (6-32)
  Overall survival               33   
    @ 1 year                          39 (22-56)
    @ 3 years                         20 (8-35)
    @ 5 years                         20 (8-35)

Abbreviations: CI: confidence interval.

###### 

Outcomes by conditioning regimen subtype

  Outcome event                  Non-myeloablative/RIC   Myeloablative   P-value                
  ------------------------------ ----------------------- --------------- --------- ------------ --------------------
  Transplant-related mortality   33                                      73                     
    @ 100days                                            9 (2-22)                  23 (14-33)   0.0437
    @ 1 year                                             15 (6-30)                 30 (20-41)   0.0742
    @ 3 years                                            19 (8-34)                 30 (20-41)   0.1803
    @ 5 years                                            19 (8-34)                 30 (20-41)   0.1803
  Relapse                                                                                       
    @ 1 year                                             65 (46-79)                27 (17-37)   0.0001
    @ 3 years                                            69 (49-82)                43 (31-54)   0.011
    @ 5 years                                            69 (49-82)                47 (35-58)   0.036
  Disease-free survival          33                                      73                     P~\_overall=0.167~
    @ 1 year                                             19 (8-34)                 43 (31-54)   0.0097
    @ 3 years                                            13 (4-27)                 27 (17-38)   0.0776
    @ 5 years                                            13 (4-27)                 22 (13-33)   0.2175
  Overall survival               35                                      96                     P~\_overall=0.128~
    @ 1 year                                             51 (33-67)                56 (45-65)   0.6248
    @ 3 years                                            16 (6-30)                 34 (25-44)   0.026
    @ 5 years                                            16 (6-30)                 25 (17-35)   0.2348

Abreviations: CI: confidence interval, RIC: reduced intensity conditioning
